A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease
Open Access
- 1 May 2020
- journal article
- research article
- Published by Elsevier BV in Transplantation and Cellular Therapy
- Vol. 26 (5), 835-844
- https://doi.org/10.1016/j.bbmt.2019.08.029
Abstract
No abstract availableKeywords
Funding Information
- Osiris Therapeutics
This publication has 28 references indexed in Scilit:
- Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III studyInternational Journal of Hematology, 2015
- A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related MortalityTransplantation and Cellular Therapy, 2015
- First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2012
- Risk factors for acute GVHD and survival after hematopoietic cell transplantationBlood, 2012
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2010
- Graft-versus-host diseaseThe Lancet, 2009
- Hematopoietic Stem-Cell TransplantationNew England Journal of Medicine, 2006
- Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cellsTransplantation, 2003
- Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility ComplexScandinavian Journal of Immunology, 2003
- Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuliBlood, 2002